The 36-month beta value for PROF is at 0.46. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PROF is 26.58M, and currently, shorts hold a 1.80% of that float. The average trading volume for PROF on June 11, 2025 was 76.92K shares.
PROF) stock’s latest price update
The stock price of Profound Medical Corp (NASDAQ: PROF) has jumped by 17.39 compared to previous close of 5.75. Despite this, the company has seen a gain of 23.18% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting.
PROF’s Market Performance
Profound Medical Corp (PROF) has seen a 23.18% rise in stock performance for the week, with a 45.79% gain in the past month and a -1.03% plunge in the past quarter. The volatility ratio for the week is 7.64%, and the volatility levels for the past 30 days are at 4.69% for PROF. The simple moving average for the past 20 days is 29.47% for PROF’s stock, with a -1.66% simple moving average for the past 200 days.
Analysts’ Opinion of PROF
Many brokerage firms have already submitted their reports for PROF stocks, with Lake Street repeating the rating for PROF by listing it as a “Buy.” The predicted price for PROF in the upcoming period, according to Lake Street is $16.50 based on the research report published on July 23, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see PROF reach a price target of $12, previously predicting the price at $9. The rating they have provided for PROF stocks is “Buy” according to the report published on July 16th, 2024.
Stifel gave a rating of “Hold” to PROF, setting the target price at $11 in the report published on November 28th of the previous year.
PROF Trading at 34.45% from the 50-Day Moving Average
After a stumble in the market that brought PROF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.89% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROF starting from Menawat Arun Swarup, who purchase 12,027 shares at the price of $4.73 back on May 16 ’25. After this action, Menawat Arun Swarup now owns 587,089 shares of Profound Medical Corp, valued at $56,888 using the latest closing price.
Menawat Arun Swarup, the CEO of Profound Medical Corp, purchase 10,003 shares at $4.33 during a trade that took place back on May 15 ’25, which means that Menawat Arun Swarup is holding 575,062 shares at $43,263 based on the most recent closing price.
Stock Fundamentals for PROF
Current profitability levels for the company are sitting at:
- -1.85 for the present operating margin
- 0.67 for the gross margin
The net margin for Profound Medical Corp stands at -2.84. The total capital return value is set at -0.38. Equity return is now at value -66.36, with -54.20 for asset returns.
Based on Profound Medical Corp (PROF), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.46. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -407.31.
Currently, EBITDA for the company is -33.06 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 13.91. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.31.
Conclusion
In conclusion, Profound Medical Corp (PROF) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
